Business Wire

GSMA: US Gets Set To Clash with Europe at WRC-19

24.10.2019 10:00:00 EEST | Business Wire | Press release

Share

A clash between the US and Europe over 5G’s future development at The World Radiocommunication Conference 2019 (WRC-19) – taking place in Egypt from 28 October to 22 November 2019 – could risk $565bn of economic expansion globally over the next 15 years, warned the GSMA today.

This economic growth from next-generation 5G services depends on the availability of a specific strand of radio frequencies, known as ‘millimetre wave’ frequencies, which are set to be identified for use by mobile operators at WRC-19. However, efforts by Europe to constrain the use of these critical frequencies due to claims of potential interference with some space services has 5G’s future hanging in the balance.

“The stakes are high - a new generation of 5G services and the economic growth accompanying them will depend on the spectrum decisions taken at WRC-19,” said Brett Tarnutzer, Head of Spectrum, GSMA. “We are calling for Europe to join the US in taking a pro-5G stance at WRC-19 to protect its digital future. Some administrations are still determined to limit mobile use of airwaves that 5G requires to reach its full potential. This protectionist attitude will have consequences for our global economy if allowed to prevail.”

“Our focus is on ensuring that all regions are on board with the win-win resolution that will allow for robust 5G deployments globally while protecting satellite interests worldwide,” said Tom Power, Senior Vice President & General Counsel, CTIA. “Reports indicate that the fastest 5G peak speeds today are in the US, and that’s because the US was the first to deploy mmWave. The benefits of using this spectrum are clear but only through global harmonization at WRC-19 will all regions gain the greatest value.”

Benefits of mmWave spectrum

mmWave bands are critical to providing ultra-high speeds and ultra-high capacity for a wide range of consumer, business and government services that require almost instantaneous delivery of large amounts of data. This includes entertainment services such as downloading ultra-high definition movies in seconds, virtual and augmented reality applications, remote surgery with ‘haptic’ feedback, precise control of industrial devices and robots, and autonomous vehicles.

Three thousand delegates from over 190 nations will meet at WRC-19 to agree on how this spectrum may be used. Different countries may have different approaches and strategies, but WRC is the meeting point for all nations to maximize the potential for 5G within their borders by thinking globally. The process of harmonization at WRC-19 delivers global roaming and economies of scale for vendors and carriers, and that translates into lower costs, faster deployments and greater convenience for consumers.

Clash over airwaves at WRC-19

The build-up to WRC-19 is a four-year process and the use of mmWave spectrum has been the subject of intense technical study throughout. WRC-19 is the final decision after a lot of analysis and technical study.

Technical studies supported by the Americas, Africa and Arab states, have demonstrated that 5G using mmWave spectrum can co-exist safely and efficiently alongside weather-sensing services, commercial satellite services and others. These were conducted within the ITU, a UN agency. In the US, the FCC developed emission limits on 5G to protect weather sensors in nearby spectrum bands. Ahead of WRC-19, the FCC and the State Department also worked with regulators from other countries throughout the Americas, achieving consensus at the CITEL conference in Ottawa in August.

Despite this body of evidence, European countries are looking to limit the use of mmWave spectrum by setting protective technical conditions.

“It is important to follow studies which make realistic assumptions about how networks will function and make the best use of the spectrum for all,” added Brett Tarnutzer. This approach is being followed in the Americas, Africa and the Middle East but we need to find a global solution, including Europe. Large ‘guard bands’ will be needed – that is empty tranches of unused spectrum separating services - if we have technical limits which are too severe. This will restrict the economic benefit we can gain from finite spectrum resources and harm consumers and industry.”

-ENDS-

About the GSMA

The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators with over 350 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.

For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:
For the GSMA
Gearóid Cashman
+44 79 7679 0169
gcashman@webershandwick.com

GSMA Press Office
pressoffice@gsma.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye